Herbert Smith Freehills Kramer is a world-leading global law firm, where our ambition is to help you achieve your goals.

Exceptional client service and the pursuit of excellence are at our core. We invest in and care about our client relationships, which is why so many are longstanding. We enjoy breaking new ground, as we have for over 170 years.

As a fully integrated transatlantic and transpacific firm, we are where you need us to be. Our footprint is extensive and committed across the world’s largest markets, key financial centres and major growth hubs.

At our best tackling complexity and navigating change, we work alongside you on demanding litigation, exacting regulatory work and complex public and private market transactions. We are recognised as leading in these areas.

We are immersed in the sectors and challenges that impact you. We are recognised as standing apart in energy, infrastructure and resources. And we’re focused on areas of growth that affect every business across the world.

All of this is achieved by supporting the growth of our people, who help us deliver on our ambition – which is to help you achieve yours.

Herbert Smith Freehills Kramer: Your goals. Our ambition

The Opportunity

Our team

Our Greater China capital markets team is equipped to provide full legal services in both debt and equity capital markets with a strong track record of advising issuers and underwriters on public offerings and private placements of debt and equity across a wide range of industry sectors.

Our ECM practice have advised many high profile and "first of its kind" IPOs including unprecedented spin-off listings, A to H listing, and simultaneous A and H dual listings. Our extensive experience dealing with complex legal structures and technical issues helps our clients to get the deal through. We also have a US securities capability which provides support on US securities laws and liability issues.  The combination of our technical excellence, reliability and customer centric approach allows us to provide an all rounded high quality service experience to our clients.

We are one of the leaders in the healthcare and biotech field particularly for advising sponsors. Since the introduction of the Listing Rules' Chapter 18A biotech/pharma changes we have advised a number of 18A healthcare listings including listings by Antengene (06996.HK), Shanghai Junshi Biosciences (01877.HK), TOT BIOPHARM (01875.HK), SinoMab Bioscience Limited (03681.HK), Peijia Medical (09996.HK), Carsgen Therapeutics (02171.HK), Brii Biosciences (02137.HK), HeartCare (06609.HK), Acotec (06669.HK), Abbisko (02256.HK) and Bioheart (02185.HK).

Team

Location

Contract type

Diversity & Inclusion

We are committed to attracting people from all backgrounds and creating a respectful and inclusive culture where everyone thrives. We see this as essential to our success, including our ability to innovate and achieve sustained high performance. This is a key part of our Values—Human, Bold, and Outstanding.